Sonoma Pharmaceuticals announced the pricing of a "best efforts" public offering of units consisting of one share of common stock, together with one half of one warrant to purchase one share of common stock at an exercise price equal to $1 per whole share. The public offering price was $1 per unit. The offering is expected to close on or about November 21, 2018, subject to customary closing conditions. Certain investors, who would beneficially own, together with its affiliates and certain related parties, more than 4.99% of the outstanding common stock as a result of the public offering, can purchase series C convertible preferred stock convertible into shares of common stock, in lieu of purchasing common stock.

Motorola Solutions announced that the U.S. International Trade Commission has issued a Notice of Final Determination confirming that certain Hytera Communications products are infringing four Motorola Solutions patents. The ITC has also issued exclusion and cease-and-desist orders for Motorola Solutions' U.S. Patent Nos. 7,369,869, 7,729,701 and 8,279,991, prohibiting Hytera from importing products into the United States and selling or marketing those products. The ITC also rejected Hytera's request to allow it to import infringing products or components into the U.S. to repair or replace those in the field. The ruling also affirms Administrative Law Judge McNamara's finding that Hytera "unquestionably copied certain of Motorola patented technologies." A mandatory 60-day presidential review period has now begun, during which the U.S. President may modify the ITC's Final Determination. The ITC's exclusion and cease-and-desist orders will take effect on approximately Jan. 15, 2019, when all Hytera products infringing Motorola Solutions' '869, '701 and '991 patents would be excluded from the U.S. market. In addition to the ITC victory, Motorola Solutions recently prevailed against Hytera in the Regional Court of Mannheim in Germany in a similar patent infringement case. Motorola Solutions will also continue to vigorously pursue its patent infringement, copyright infringement and trade secret theft lawsuits against Hytera in the U.S. District Court for the Northern District of Illinois, the Regional Court of Dusseldorf in Germany, the Federal Court of Australia and other jurisdictions around the world.

In a regulatory filing, Aqua America CEO Chris Franklin disclosed the purchase of 25,421.23 common shares of the company at a price of $32.86 per share.

Aquestive Therapeutics announced it received a complete response letter from the U.S. Food and Drug Administration in regards to its New Drug Application for tadalafil oral film. Tadalafil is a PDE5 inhibitor currently marketed in tablet form for the treatment of erectile dysfunction and benign prostatic hyperplasia under the brand name Cialis, and for treatment of pulmonary arterial hypertension under the brand name Adcirca. In the letter, the FDA requested limited additional data from healthy volunteers. The company has also notified the agency about its plans to engage an alternative supplier of the active pharmaceutical ingredient.

Daktronics announced that its Board of Directors adopted a new shareholder rights agreement that will take effect when the current plan, adopted in 2008, expires on November 19, 2018. In connection with the adoption of the rights agreement, the Board declared a dividend of one right for each share of common stock outstanding at the close of business on November 19, 2018 and for each share of common stock issued after that date and before the rights are triggered or redeemed. The rights are designed to enable Daktronics shareholders to realize the full long-term value of their investment and to provide for fair and equal treatment of all shareholders if an unsolicited attempt is made to acquire Daktronics. Daktronics believes that the rights agreement will enable its Board to be in a better position to perform its fiduciary duties and help the Board to protect shareholders against abusive takeover tactics that may be used to gain control of the company without paying a price that is in the best interest of all shareholders. The rights agreement was not adopted in response to any known offers for Daktronics and is similar to rights agreements adopted by other companies. The rights agreement, which was adopted by the Board of Daktronics after evaluation and consultation with advisors of Daktronics, has no immediate dilutive effect and does not prevent Daktronics or its shareholders from accepting a fair offer to acquire Daktronics in a negotiated transaction. The rights will be exercisable only if a person or group acquires 20% or more of Daktronics' common stock or announces a tender offer, the consummation of which would result in ownership by a person or group of 20% or more of the common stock. Each right will initially entitle shareholders to buy one-one thousandth of one share of preferred stock per common share owned at an initial exercise price of $25.00 per right, subject to adjustment. At that time, Daktronics' shareholders (other than the acquirer, whose rights will have become void and will not be exercisable) would have the right to purchase, at a price equal to 50% of the common stock's market value, a number of shares of Daktronics' common stock equal to (a) the exercise price of $25.00 multiplied by the number of one one-thousandth of a share of preferred stock for which a right was exercisable divided by (b) 50% of the then current market value of Daktronics' common stock. Daktronics' Board of Directors may redeem the rights for $0.001 per right at any time before the rights become exercisable. Unless the rights are redeemed, exchanged or terminated earlier, they will expire on November 19, 2021. At any time after any person or group acquires beneficial ownership of 20% or more of Daktronics' common stock, the Board of Daktronics, at its option, may exchange each right (other than the rights owned by the acquirer, which will have become void), in whole or in part, for shares of Daktronics' common stock at an exchange ratio of one share of common stock per outstanding right.

Maxar Technologies announced that shareholders approved the company's U.S. domestication at a special meeting held earlier today in Westminster, Colorado. A total of 227 holders of common shares of the company, representing approximately 76% of the company's issued and outstanding common shares, voted in connection with the meeting, with 99.8% voting in favor of the U.S. domestication and more than 99.8% of the common shares and LTIP Units voted at the meeting, voting as a single class, voted in favor of the U.S. domestication. Following the U.S. domestication effective date, Maxar will continue to list its shares on both the New York Stock Exchange and Toronto Stock Exchange. Maxar does not anticipate that the U.S. domestication will have any impact on its employees, customers, suppliers, or other key stakeholders. As previously announced, Maxar will transition to U.S. GAAP accounting standards and U.S. domestic securities filings effective with its U.S. domestication. The company believes this transition will make its financial results more transparent to a wider audience of investors and provide increased comparability with U.S. aerospace and defense peer companies. Subject to obtaining required court approvals, as well as the satisfaction of other conditions precedent, Maxar anticipates that the U.S. domestication will be completed on or about January 1, 2019.

In a regulatory filing, Equinix Asia Pacific president Yau Tat Lee disclosed the sale of 2,792 common shares of the company at a price of $382.8639.